(HealthDay): For outpatients with mild to moderate COVID-19 at high risk of progression to severe disease, bamlanivimab infusion plus etesevimab leads to a lower incidence of hospitalization and death from COVID-19, according to a study published online July 14 at New England Journal of Medicine.
Michael Dougan, MD, Ph.D., of Massachusetts General Hospital in Boston, and colleagues randomly assigned a cohort of outpatients with mild to moderate COVID-19 with a high risk of disease progression severe to receive a single intravenous infusion of neutralizer. monoclonal-antibody combination agent (bamlanivimab and etesevimab) or placebo (518 and 517 patients, respectively) three days after the diagnosis of severe acute respiratory syndrome of coronavirus 2.
The researchers found that at day 29, 2.1 and 7.0 percent of patients in the bamlanivimab-etesevimab and placebo groups, respectively, had hospitalization related to COVID-19 or death for any reason (absolute risk difference, -4.8 percent; relative risk difference, 70 percent). No deaths were reported in the bamlanivimab-etesevimab group, while in the group ten deaths occurred. placebo group, nine of which were designated related to COVID-19. A greater reduction from baseline in viral load was observed at day 7 among patients receiving bamlanivimab plus etesevimab versus placebo (difference in baseline). placebo instead with respect to the baseline, -1.20).
“As society moves toward the end of the COVID-19 pandemic with widespread vaccination campaigns and efforts to achieve herd immunity, antibody therapy provides a potential treatment option to reduce the incidence of disease and death among vulnerable patients “, write the authors.
Several authors revealed financial links with biopharmaceutical companies, including Eli Lilly, who manufactures bamlanivimab plus etesevimab and funded the study.
Summary / Full text
Copyright © 2021 HealthDay. All rights reserved.
Citation: Neutralizing Monoclonal Antibody Combination Treats Mild and Moderate COVID-19 (2021, July 16) Retrieved July 17, 2021 from https://medicalxpress.com/news/2021-07-neutralizing-monoclonal-antibody -combo-mild.html
This document is subject to copyright. Apart from any fair treatment for private study or research purposes, no part may be reproduced without written permission. Content is provided for informational purposes only.